Gilead Sciences (GILD) Enterprise Value (2009 - 2026)

Gilead Sciences (GILD) has reported Enterprise Value for 18 consecutive years, with $153.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 15.95% year-over-year to $153.5 billion; the trailing twelve-month figure through Jun 2026 stood at $153.5 billion (up 15.95% YoY), and the FY2025 full-year result was $144.6 billion, up 37.69% from the prior year.
• Enterprise Value fell to $153.5 billion in Q2 2026 per GILD's latest filing, from $165.4 billion in the prior quarter.
• Across five years, Enterprise Value topped out at $165.4 billion in Q1 2026 and bottomed at $69.3 billion in Q1 2022.
• Historically, Enterprise Value has averaged $106.2 billion across 5 years, with a median of $98.5 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value dropped 12.51% in 2022, then jumped 60.23% in 2025.
• Over 5 years, Enterprise Value stood at $100.6 billion in 2022, then fell by 7.0% to $93.6 billion in 2023, then increased by 12.21% to $105.0 billion in 2024, then surged by 37.69% to $144.6 billion in 2025, then increased by 6.17% to $153.5 billion in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $153.5 billion, $165.4 billion, and $144.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.